Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.48 USD
+0.09 (2.50%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $3.47 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ALDX 3.48 +0.09(2.50%)
Will ALDX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Other News for ALDX
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra announces advancement of new RASP modulators, preclinical data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aldeyra Therapeutics (ALDX), Cardinal Health (CAH) and Roche Holding AG (OtherRHHVF)
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap